Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma

Purpose To assess the 12-month efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT) with or without bimatoprost 0.01% (BIM) in primary open-angle glaucoma (POAG), including normal-tension glaucoma (NTG). Study design Prospective, multicenter, open-label stud...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of ophthalmology 2021-03, Vol.65 (2), p.295-305
Main Authors: Park, Sang Woo, Kim, Joon Mo, Lee, Ji Woong, Maglambayan, Joy, Simonyi, Susan, Park, Ki Ho
Format: Article
Language:English
Subjects:
Adverse events
Clinical Investigation
Eye (anatomy)
Glaucoma
Hyperemia
Intraocular pressure
Medicine
Medicine & Public Health
Ophthalmology
Pharmacovigilance
Reduction
Safety
Timolol
Visual field
Visual fields
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To assess the 12-month efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT) with or without bimatoprost 0.01% (BIM) in primary open-angle glaucoma (POAG), including normal-tension glaucoma (NTG). Study design Prospective, multicenter, open-label study. Methods FCBT was self-administered twice daily after applicable washout (study eye). Intraocular pressure (IOP) was measured at baseline and months 1, 3, 6, 9, and 12. BIM could be added for IOP ≥ 21 mmHg, IOP reduction from baseline 
ISSN:0021-5155
1613-2246
DOI:10.1007/s10384-020-00796-3